These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7846753)

  • 1. Cyclosporine disposition and metabolite profiles in renal transplant patients receiving a microemulsion formulation.
    Kovarik JM; Vernillet L; Mueller EA; Freiburghaus R; Niederberger W; Kutz K
    Ther Drug Monit; 1994 Oct; 16(5):519-25. PubMed ID: 7846753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation.
    Mueller EA; Kovarik JM; van Bree JB; Lison AE; Kutz K
    Transplantation; 1994 Apr; 57(8):1178-82. PubMed ID: 8178343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients.
    Kovarik JM; Mueller EA; van Bree JB; Arns W; Renner E; Kutz K
    Ther Drug Monit; 1994 Jun; 16(3):232-7. PubMed ID: 8085277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine pharmacokinetics and variability from a microemulsion formulation--a multicenter investigation in kidney transplant patients.
    Kovarik JM; Mueller EA; van Bree JB; Flückiger SS; Lange H; Schmidt B; Boesken WH; Lison AE; Kutz K
    Transplantation; 1994 Sep; 58(6):658-63. PubMed ID: 7940685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
    Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
    Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients].
    Sperschneider H; Wagner C; Korn A; Christians U
    Med Klin (Munich); 1997 Oct; 92(10):589-96. PubMed ID: 9446006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation.
    Kovarik JM; Mueller EA; Richard F; Niese D; Halloran PF; Jeffery J; Paul LC; Keown PA
    Transplantation; 1996 Sep; 62(6):759-63. PubMed ID: 8824473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers.
    Kees F; Bucher M; Schweda F; Gschaidmeier H; Burhenne J; Mikus G; Faerber L
    Ther Drug Monit; 2006 Jun; 28(3):312-20. PubMed ID: 16778713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period.
    Wahlberg J; Wilczek HE; Fauchald P; Nordal KP; Heaf JG; Olgaard K; Hansen JM; Lokkegaard H; Mueller EA; Kovarik JM
    Transplantation; 1995 Oct; 60(7):648-52. PubMed ID: 7570970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).
    Noble S; Markham A
    Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation.
    Coukell AJ; Plosker GL
    Pharmacoeconomics; 1998 Dec; 14(6):691-708. PubMed ID: 10346420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of the conventional and microemulsion formulations of cyclosporine in pancreas-kidney transplant recipients with gastroparesis.
    van der Pijl JW; Srivastava N; Denouël J; Burggraaf J; Schoemaker RC; van der Woude FJ; Cohen AF
    Transplantation; 1996 Aug; 62(4):456-62. PubMed ID: 8781610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equivalence of cyclosporine blood level assays in patients receiving cyclosporine microemulsion or cyclosporine. The Sandoz Neoral Study Group N103.
    Pescovitz MD; Wong RL; Choc MG; Chang CT
    Clin Transplant; 1997 Oct; 11(5 Pt 1):442-5. PubMed ID: 9361938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation.
    Mueller EA; Kovarik JM; van Bree JB; Tetzloff W; Grevel J; Kutz K
    Pharm Res; 1994 Feb; 11(2):301-4. PubMed ID: 8165192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine a in rats.
    Koehler J; Kuehnel T; Kees F; Hoecherl K; Grobecker HF
    Drug Metab Dispos; 2002 Jun; 30(6):658-62. PubMed ID: 12019192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral.
    Ritschel WA
    Clin Transplant; 1996 Aug; 10(4):364-73. PubMed ID: 8884110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group.
    Keown P; Landsberg D; Halloran P; Shoker A; Rush D; Jeffery J; Russell D; Stiller C; Muirhead N; Cole E; Paul L; Zaltzman J; Loertscher R; Daloze P; Dandavino R; Boucher A; Handa P; Lawen J; Belitsky P; Parfrey P
    Transplantation; 1996 Dec; 62(12):1744-52. PubMed ID: 8990355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
    Keown P; Niese D
    Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose and steady state pharmacokinetics of CSA and two main primary metabolites, AM1 and AM4n in patients with rheumatic/autoimmune diseases.
    Suchy D; Dostalek M; Perinova I; Brozmanova H; Grundmann M; Vyskocil V; Mayer O
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Sep; 155(3):269-74. PubMed ID: 22286813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplant using a microemulsion formulation.
    Chapman JR; O'Connell PJ; Bovington KJ; Allen RD
    Transplantation; 1996 Jun; 61(12):1699-704. PubMed ID: 8685946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.